Related Experiment Video
Updated: Jul 25, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
Whole inactivated SIV virion vaccines with functional envelope glycoproteins: safety, immunogenicity, and activity
J D Lifson1, M Piatak, J L Rossio
1AIDS Vaccine Program, SAIC Frederick, National Cancer Institute at Frederick, MD 21702, USA. lifson@avpaxp1.ncifcrf.gov
Abstract:
A novel type of whole inactivated simian immunodeficiency virus (SIV) virion vaccine immunogen with functional envelope glycoproteins was evaluated, without adjuvant, in rhesus macaques. Immunogens included purified inactivated virions of SIVmac239, a designed mutant of SIVmac239 with gp120 carbohydrate attachment sites deleted (SIVmac239 g4,5), and SIVmneE11S. The vaccines were noninfectious, safe, and immunogenic, inducing antibody responses and cellular responses, including responses by CD8+ lymphocytes. Interpretation of protective efficacy following intrarectal challenge was complicated by incomplete take of the challenge in some SIV naïve controls.
Related Concept Videos
Vaccinations
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccines
Poliomyelitis
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly

